One-year inhibition of tumor necrosis factor-α: A major success or a larger puzzle?

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 209-213

  Graninger, Winfried B ^a   Smolen, Josef S ^a,a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; JOINT DESTRUCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RECOMBINANT FUSION PROTEINS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035004502     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00010     Document Type: Article

References (59)

1. 1 Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. These are the 1-year results from the ATTRACT trial showing the clinical benefit and the halt of radiographic progression in RA patients treated with methotrexate and concomitant infiximab.
2. 2 Maini R, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, ATTRACT Study Group, Lancet 1999, 354:1932-1939.
3. 3 van Riel PL, van Gestel AM: Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000, 59(suppl):128-131.
4. 4 Lipsky PE, van der Hejde D, St Clair W, et al.: 102-WK clinical radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab in patients with active RA despite MTX. Arthritis Rheum 2000, 43(suppl):S269.
5. 5 Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. In this controlled, randomized trial, 40% of RA patients who had not responded to methotrexate alone had a 50% reduction in the American College of Rheumatology response criteria to the combination of etanercept plus methotrexate given for 6 months; however, radiographs were not studied.
6. 6 Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
7. 7 Elliott MJ, Maini RN, Feldmann M, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
8. 8 Van de Putte LBA, Rau R, Breedveld F, et al.: One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum 2000, 43(suppl):S269.
9. 9 Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
10. 10 Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593. In this first trial of a TNF-blocker in early RA (up to 3 years' duration), etanercept compared with methotrexate appeared to act more rapidly in decreasing joint symptoms and radiographic damage.
11. 11 Genovese MC, Martin RW, Fleischmann RM, et al.: Etanercept vs. MTX in early rheumatoid arthritis; two year follow-up. Arthritis Rheum 2000, 43(suppl):S269.
12. 12 Mathias SD, Colwell HH, Miller DP, et al.: health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000, 22:128-139.
13. 13 Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor amelio-rates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89:9784-9788.
14. 14 Brennan FM, Chantry D, Jackson A, et al.: Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247.
15. 15 Maini RN, Eiliott MJ, Brennan FM, et al.: Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995, 144:195-223.
16. 16 Choi HK, Seeger JD, Kuntz KM.: A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000, 43:2318-2327.
17. 17 Smolen JS, Breedveld FC, Burmester GR, et al.: Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000, 59:504-505.
18. 18 Furst DE, Breedveld FC, Burmester GR, et al.: Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis. Ann Rheum Dis 2000, 59(suppl):l1-l2.
19. 19 Butler DM, Maini RN, Feldmann M, et al.: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995, 6:225-230.
20. 20 Tak PP, Taylor PC, Breedveld FC, et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081.
21. 21 Taylor PC, Peters AM, Paleolog E, et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47.
22. 22 Ulfgren AK, Andersson U, Engstrom M, et al.: Systemic anti-tumor necrosis factor alpha therapy in rheumatoid tumor necrosis factor alpha synthesis. Arthritis Rheum 2000, 43:2391-2396.
23. 23 Maini RN, Elliott MJ, Brennan FM, et al.: Beneficial effects of tumour necrosis factor-alpha (TNF-aipha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995, 101:207-212.
24. 24 Brennan FM, Browne KA, Green PA, et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997, 36:643-650.
25. 25 Ohshima S, Saeki Y, Mima T, et al.: Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 2000, 19:305-313.
26. 26 Maini RN, Taylor PC, Paleolog E, et al.: Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999, 58(suppl):l56-l60.
27. 27 Van den Bosch F, Kruithof E, Baeten D, et al.: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000, 59:6-33.
28. 28 Brandt J, Haibel H, Comely D, et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal anti-body infliximab. Arthritis Rheum 2000, 43:1346-1352. The short-term application of infliximab improved signs and symptoms of ankylosing spondylitis in 10 patients.
29. 29 Gorman J, Sack K, Davis J: Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind placebo-controlled study. Arthritis Rheum 2000, 43(suppl):S403.
30. 30 Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. In this 12-week placebo-controlled study, 87% of etanercept-treated patients met the psoriasis arthritis response criteria, compared with 23% of placebo-patients. The skin index improved by almost 50% in the treatment group.
31. 31 Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342:733-769. Exciting results for children with active polyarticular juvenile rheumatoid arthritis and their parents: three quarters of patients responded to etanercept in an open-label study. Responders could participate in a double-blind controlled trial showing that treatment with etanercept leads to significant improvement in these patients. Etanercept is well tolerated by pediatric patients.
32. 32 Braun J, Sieper J: Anti-TNF alpha: a new dimension in the pharmacotherapy of the spondyloarthropathies!? Ann Rheum Dis 2000, 59:404-406.
33. 33 Mori L, Iselin S, De Libero G, et al.: Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-lgG1-treated and TNFR1-deficierit mice. J Immunol 1996, 157:3178-3182.
34. 34 van den Berg WB: Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000, 59(suppl)1:1B1-1B4.
35. 35 Probert L, Plows D, Kontogeorgos G, et al.: The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995, 25:1794-1797.
36. 36 Bresnihan B, Alvaro-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204. This placebo-controlled trial shows the capability of an interleukin-1 inhibitor to slow joint destruction in a dose-proportional manner.
37. 37 Bresnihan B, Newmark RD, Robbins S, et al: Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. Arthritis Rheum 2000, 43(suppl):S289.
38. 38 Nishimoto N, Kishimoto T, Yoshizaki K: Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59(suppl):l21-l27.
39. 39 Gravallese EM, Manning C, Tsay A, et al.: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258. Ex vivo study demonstrating the presence of osteoclasts at the site of bone erosions in RA, Osteoclast differentiation factor (also known as osteoprotegerin ligand) is expressed both by synovial fibroblasts and by activated T lymphocytes derived from synovial tissues from patients with RA. This may contribute directly to the expansion of osteoclast precursors and to the formation and activation of osteoclasts at sites of bone erosion in RA.
40. 40 Takayanagi H, Iizuka H, JuJi T, et al.: Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-289.
41. 41 Goldring SR, Gravallese EM: Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000, 2:33-37.
42. 42 Itonaga I, Fujikawa Y, Sabokbar A, et al.: Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000, 192:97-104.
43. 43 Goldring SR, Gravallese EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000, 12:195-199.
44. 44 Kong YY, Feige U, Sarosi I, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-308.
45. 45 Schett G, Tohidast-Akrad M, Smolen JS, et al.: Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000, 43:2501-2512. Immunoblotting and immunohistology study showing the presence in distinct parts of the RA synovium of activated forms of kinases that are involved in the signaling of TNF and interleukin-1. The results provide a rationale for clinical trials of kinase inhibitors in RA.
46. 46 Aggarwal BB: Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappa B. Ann Rheum Dis 2000, 59(suppl):l6-l16.
47. 47 Han Z, Boyle DL, Manning AM, et al.: P-1 and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998, 28:197-208.
48. 48 Han Z, Boyle DL, Aupperle KR, et al.: Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999, 291:124-130.
49. 49 Sen M, Lauterbach K, El Gabalawy H, et al.: Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 2000, 97:2791-2796. The unusual phenotypic properties of RA fibroblasts may be attributable partly to their replacement with primitive fibroblast-like synoviocytes with characteristics of immature bone marrow and mesenchymal cells. Understanding the signaling pathways of embryonic growth factors, which are overexpressed in RA synovium, may yield new targets for therapeutic intervention.
50. 50 Anonymous: Novel N-hydroxamic acid hydrazide inhibitors of TNF-alpha synthesis. Expert Opin Ther Pat 2000, 10:1517-1621.
51. 51 Wadsworth SA, Cavender DE, Beers SA, et al.: RWJ 67857, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999, 291:680-687.
52. 52 Hernandez-Pando R, Orozco H, Arriaga K, et al.: Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice. Int J Exp Pathol 2000, 81:199-209.
53. 53 Ku G, Faust T, Lauffer LL, et al.: Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 1996, 8:377-386.
54. 54 Smolen JS, Kalden JR, Scott DL, et al.: Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicenter trial. European Leflunomide Study Group. Lancet 1999, 353:259-266.
55. 55 Manna SK, Mukhopadhyay A, Aggarwal BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000, 165:5962-5969.
56. 56 Steiner G, Tohidast-Akrad M, Witzmann G, et al.: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999, 38:202-213.
57. 57 Schulze-Koops H, Davis LS, Haverty TP, et al.: Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol 1998, 25:2065-2076.
58. 58 Morgan A, Hale G, Waldmann H, et al.: Prolonged combination therapy of RA using CD4 and TNF-alpha blockade: a pilot study. Arthritis Rheum 1998, 41(suppl):S55.
59. 59 Williams RO, Ghrayeb J, Feldmann M, et al.: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 84:433-439.